论文部分内容阅读
目的探讨纳络酮治疗肺性脑病临床疗效及安全性。方法将入选120例病例随机分为治疗组及对照组,两组均予以抗感染、持续低流量吸氧(给氧浓度为25%～35%,氧流量为1～3L/min,鼻导管给氧法)解痉平喘、止咳化痰、保持呼吸道通畅、维持酸减、水、电解质平衡、营养支持等综合治疗。治疗组在此基础上加用纳络酮注射液(0.4mg/支),首剂负荷量0.8mg,加入5%葡萄糖20ml中静脉推注,连用3d。结果治疗组总有效率显著高于对照组(P<0.05);动脉血气分析指标(PaO2)显著高于对照组(P<0.05);动脉血二氧化碳分压(PaCO2)显著低于对照组(P<0.05);治疗过程中无不良反应发生。结论纳洛酮治疗肺性脑病疗效确切、安全。
Objective To investigate the clinical efficacy and safety of naloxone in the treatment of pulmonary encephalopathy. Methods A total of 120 cases were randomly divided into treatment group and control group. Both groups were given anti-infection, continuous low-flow oxygen (oxygen concentration of 25% -35%, oxygen flow of 1 ~ 3L / min, Oxygen) spasm and asthma, cough and phlegm, maintain airway patency, maintain acid reduction, water, electrolyte balance, nutritional support and other comprehensive treatment. On the basis of this, the treatment group added naloxone injection (0.4mg / support), the first dose of 0.8mg, add 5% glucose 20ml intravenous bolus, once every 3d. Results The total effective rate of the treatment group was significantly higher than that of the control group (P <0.05); PaO2 of arterial blood gas analysis was significantly higher than that of the control group (P <0.05); PaCO2 of arterial blood was significantly lower than that of the control group <0.05). No adverse reactions occurred during the course of treatment. Conclusion Naloxone is effective and safe in the treatment of pulmonary encephalopathy.